NVO files an NDA with the FDA for once-weekly CagriSema, a combo obesity injection showing superior weight loss in obese patients in phase III studies.

The perception of GLP-1s — and the people who use them — is getting better, but work still must be done to avoid stigma.

A recent study from the University of Cape Town reveals a concerning double burden of malnutrition among young children in ...

Research collected by University of Guelph post doctoral scholar Megan Ross as part of her recent PhD work from the Atlantic ...

The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.

Novo Nordisk filed an FDA application for weekly CagriSema after trials showed up to 22.7% weight loss versus placebo.

Parents in Wiltshire might want to put the chocolates on a high shelf and keep an eye on the fizzy drinks this Christmas, after the ...

Retatrutide treatment resulted in significant improvements in WOMAC pain scores and body weight compared with placebo in the TRIUMPH-4 trial.

Parents in Wiltshire might want to put the chocolates on a high shelf and keep an eye on the fizzy drinks this Christmas, ...

NVO seeks approval for a 7.2 mg Wegovy dose after study data showed stronger weight loss that can challenge Zepbound's U.S.

AstraZeneca ($AZN) announced an update on their ongoing clinical study. Study Overview AstraZeneca is running a Phase IIb study called “A Phase ...